{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T21:08:23Z","timestamp":1789247303875,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40121-026-01365-w","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:23:39Z","timestamp":1786040619000},"page":"2737-2750","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Can We Compare Adverse Events\u2019 Attributable Risk Using a Self-Controlled Case Series Design for Vaccine Safety? A Guillain-Barr\u00e9 Syndrome Use Case"],"prefix":"10.1007","volume":"15","author":[{"given":"Caihua","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica L.","family":"Chilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott P.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen L.","family":"Dooling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Maddalena","family":"Lino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Lewnard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradford D.","family":"Gessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Begier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"issue":"3","key":"1365_CR1","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1517\/14740338.2011.562187","volume":"10","author":"A Grosso","year":"2011","unstructured":"Grosso A, Douglas I, MacAllister R, Petersen I, Smeeth L, Hingorani AD. Use of the self-controlled case series method in drug safety assessment. Expert Opin Drug Saf. 2011;10(3):337\u201340. https:\/\/doi.org\/10.1517\/14740338.2011.562187.","journal-title":"Expert Opin Drug Saf"},{"issue":"8","key":"1365_CR2","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1093\/aje\/kwu322","volume":"181","author":"MA Baker","year":"2015","unstructured":"Baker MA, Lieu TA, Li L, et al. A vaccine study design selection framework for the postlicensure rapid immunization safety monitoring program. Am J Epidemiol. 2015;181(8):608\u201318. https:\/\/doi.org\/10.1093\/aje\/kwu322.","journal-title":"Am J Epidemiol"},{"key":"1365_CR3","unstructured":"Centers for Disease Control and Prevention. Guillain\u2013Barr\u00e9 Syndrome (GBS) and Vaccines. https:\/\/www.cdc.gov\/vaccine-safety\/about\/guillain-barre.html. Accessed 28 Feb 2025."},{"issue":"1","key":"1365_CR4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1080\/14760584.2023.2211165","volume":"22","author":"SR Eiffert","year":"2023","unstructured":"Eiffert SR, Raman SR. Re: \u201cSelf-controlled case series design in vaccine safety: a systematic review\u201d - absolute and relative measures. Expert Rev Vaccines. 2023;22(1):419\u201320. https:\/\/doi.org\/10.1080\/14760584.2023.2211165.","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"1365_CR5","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/pds.3337","volume":"22","author":"K Wilson","year":"2013","unstructured":"Wilson K, Hawken S. Drug safety studies and measures of effect using the self-controlled case series design. Pharmacoepidemiol Drug Saf. 2013;22(1):108\u201310. https:\/\/doi.org\/10.1002\/pds.3337.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1365_CR6","unstructured":"Szklo M, Nieto FJ. Epidemiology: Beyond the Basics. Epidemiology: Beyond the Basics. Jones & Bartlett Publishers; 2007:83\u20139. https:\/\/lib.zu.edu.pk\/ebookdata\/Public%20Health\/Epidemiology%20Beyond%20the%20Basics-by%20Moyses%20Szklo,%20F.%20Javier%20Nieto.pdf. Accessed 7 Feb 2025."},{"key":"1365_CR7","doi-asserted-by":"publisher","unstructured":"Lloyd PC, Shah PB, Zhang HT, et al. Evaluation of Guillain\u2013Barr\u00e9 Syndrome following Respiratory Syncytial Virus Vaccination among Medicare Beneficiaries 65 Years and Older. medRxiv. 2025. https:\/\/doi.org\/10.1101\/2024.12.27.24319702v1.","DOI":"10.1101\/2024.12.27.24319702v1"},{"issue":"12","key":"1365_CR8","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1001\/jamainternmed.2021.6227","volume":"181","author":"R Goud","year":"2021","unstructured":"Goud R, Lufkin B, Duffy J, et al. Risk of Guillain\u2013Barr\u00e9 syndrome following recombinant zoster vaccine in Medicare beneficiaries. JAMA Intern Med. 2021;181(12):1623\u201330. https:\/\/doi.org\/10.1001\/jamainternmed.2021.6227.","journal-title":"JAMA Intern Med"},{"issue":"6","key":"1365_CR9","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1093\/aje\/kwt051","volume":"178","author":"LL Polakowski","year":"2013","unstructured":"Polakowski LL, Sandhu SK, Martin DB, et al. Chart-confirmed Guillain\u2013Barr\u00e9 syndrome after 2009 H1N1 influenza vaccination among the Medicare population, 2009-2010. Am J Epidemiol. 2013;178(6):962\u201373. https:\/\/doi.org\/10.1093\/aje\/kwt051.","journal-title":"Am J Epidemiol"},{"issue":"32","key":"1365_CR10","doi-asserted-by":"publisher","first-page":"696","DOI":"10.15585\/mmwr.mm7332e1","volume":"73","author":"A Britton","year":"2024","unstructured":"Britton A, Roper LE, Kotton CN, et al. Use of respiratory syncytial virus vaccines in adults aged \u226560 years: Updated recommendations of the Advisory Committee on Immunization Practices - United States, 2024. MMWR Morb Mortal Wkly Rep. 2024;73(32):696\u2013702. https:\/\/doi.org\/10.15585\/mmwr.mm7332e1.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1365_CR11","unstructured":"Melgar M and Britton A. RSV Vaccination in Adults: Work Group Interpretations. Centers for Disease Control and Prevention Advisory Committee on Immunization Practices; 24 Oct 2024. https:\/\/www.cdc.gov\/acip\/downloads\/slides-2024-10-23-24\/06-RSV-Adult-Melgar-508.pdf."},{"issue":"2","key":"1365_CR12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.vaccine.2022.11.003","volume":"41","author":"K Moll","year":"2023","unstructured":"Moll K, Lufkin B, Fingar KR, et al. Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019\u20132020. Vaccine. 2023;41(2):333\u201353. https:\/\/doi.org\/10.1016\/j.vaccine.2022.11.003.","journal-title":"Vaccine"},{"key":"1365_CR13","unstructured":"Kelly SP, et al. Temporal Trends in the Incidence of Guillain\u2013Barr\u00e9 Syndrome in the United States from 2017 to 2023. (Manuscript submitted)"},{"key":"1365_CR14","unstructured":"Prescribing Information. Shingrix\/Recombinant Zoster Vaccine. 2017. https:\/\/www.fda.gov\/media\/108597\/download?attachment. Accessed 28 Feb 2025."},{"key":"1365_CR15","unstructured":"Prescribing Information. BOOSTRIX. 2005. https:\/\/www.fda.gov\/media\/124002\/download. Accessed 28 Feb 2025."},{"key":"1365_CR16","unstructured":"Prescribing Information. FLUAD QUADRIVALENT. 2020. https:\/\/www.fda.gov\/media\/135432\/download. Accessed 28 Feb 2025."},{"key":"1365_CR17","unstructured":"Prescribing Information. Adacel. 2005. https:\/\/www.fda.gov\/media\/119862\/download. Accessed 28 Feb 2025."},{"key":"1365_CR18","unstructured":"Prescribing Information. IMOVAX. 2019. https:\/\/www.fda.gov\/media\/75709\/download. Accessed 28 Feb 2025."},{"issue":"8","key":"1365_CR19","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1093\/cid\/ciu005","volume":"58","author":"C Vellozzi","year":"2014","unstructured":"Vellozzi C, Iqbal S, Broder K. Guillain\u2013Barr\u00e9 syndrome, influenza, and influenza vaccination: the epidemiologic evidence. Clin Infect Dis. 2014;58(8):1149\u201355. https:\/\/doi.org\/10.1093\/cid\/ciu005.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"1365_CR20","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2060668","volume":"18","author":"CB Janusz","year":"2022","unstructured":"Janusz CB, Anderson TC, Leidner AJ, Lee GM, Dooling K, Prosser LA. Projected risks and health benefits of vaccination against herpes zoster and related complications in US adults. Hum Vaccin Immunother. 2022;18(5):2060668. https:\/\/doi.org\/10.1080\/21645515.2022.2060668.","journal-title":"Hum Vaccin Immunother"},{"key":"1365_CR21","unstructured":"Prescribing Information. ABRYSVO. 2023. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=19589. Accessed 28 Feb 2025."},{"key":"1365_CR22","unstructured":"GlaxoSmithKline Biologicals. AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) for injectable suspension, for intramuscular use. https:\/\/www.fda.gov\/media\/167805\/download?attachment. Accessed 28 Feb 2025."}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01365-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01365-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01365-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T20:41:46Z","timestamp":1789245706000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-026-01365-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1365"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01365-w","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Caihua Ling, Erica L. Chilson, Joanne Wu, Scott P. Kelly, Qing Liu, Kathleen L. Dooling, Maria Maddalena Lino, and Elizabeth Begier are employees of Pfizer and may hold stock or stock options. Bradford D. Gessner was employed at Pfizer during the study and manuscript development and may have held stock or stock options. Joseph A. Lewnard has received research grants, honoraria, and speaker fees from Pfizer Inc. for related\/unrelated work; research grants and honoraria from Merck, Sharp, & Dohme for unrelated work; honoraria from Valneva for unrelated work; consulting fees from Seqirus Inc. for unrelated work; and honoraria from VaxCyte for unrelated work.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics committee approval was not required for this study as all data used in this study were derived from published studies cited in this article.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}